Stocklytics Platform
Asset logo for symbol MDGL
Madrigal Pharmaceuticals
MDGL49
$233.39arrow_drop_down3.47%-$8.41
Asset logo for symbol MDGL
MDGL49

$233.39

arrow_drop_down3.47%
Key Stats
Open$239.03
Prev. Close$241.80
EPS-25.56
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range232.42
241.62
52 Week Range119.76
299.98
Ratios
Revenue-
EBITDA Margin %-
EPS-25.56
Fundamentals
Gross Profit-
Payout Ratio-
Industry average yield2.93%
Last Dividend pay dateJul 25, 2016
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

MDGL-
US Healthcare Sector-
US Market-
check_circle

MDGL / Market

MDGL exceeded the US Market which returned -0.09% over the last twenty four hours.
check_circle

MDGL / Healthcare Sector

MDGL exceeded the US Healthcare sector which returned 0.72% over the last twenty four hours.

Madrigal Pharmaceuticals (MDGL) Statistics

Madrigal Pharmaceuticals Inc (MDGL) is a leading biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiovascular diseases. As a key player in the healthcare sector, MDGL has attracted significant attention from investors and analysts alike. Understanding the statistics and valuation metrics of MDGL is crucial for assessing the company's financial performance.
When it comes to valuation metrics, MDGL has demonstrated impressive figures. Its enterprise value-to-EBITDA ratio, an important measure of a company's operational performance and profitability, indicates a healthy financial position. Moreover, MDGL's profit margin reflects its ability to generate strong returns on sales, further solidifying its market reputation.
add Madrigal Pharmaceuticals  to watchlist

Keep an eye on Madrigal Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Madrigal Pharmaceuticals (MDGL) stock's performance compared to its sector and the market over the past year?

Over the past year, Madrigal Pharmaceuticals (MDGL) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 23.31%, Madrigal Pharmaceuticals has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 63.77%, it has fallen short of the market average. This comparison highlights Madrigal Pharmaceuticals 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Madrigal Pharmaceuticals (MDGL) stock?

The PE ratio for Madrigal Pharmaceuticals (MDGL) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Madrigal Pharmaceuticals (MDGL) stock?

The Earnings Per Share (EPS) for Madrigal Pharmaceuticals (MDGL), calculated on a diluted basis, is -$25.56. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Madrigal Pharmaceuticals (MDGL) stock?

The operating margin for Madrigal Pharmaceuticals (MDGL) is -1.11K%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Madrigal Pharmaceuticals (MDGL) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Madrigal Pharmaceuticals (MDGL) is -$529.57M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Madrigal Pharmaceuticals (MDGL) have?

Madrigal Pharmaceuticals (MDGL) has a total debt of $118.06M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$381.53M.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media